MICHAEL W. BONNEY

Corporate Board Profile

Tech Score: 0/100

abrdn Healthcare Investors

Filing Date	Source Excerpt
2012-04-30	Mr. Bonney is the President, Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry.
2013-04-25	Mr. Bonney is the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He holds an BA degree from Bates College.
2014-04-30	Mr. Bonney is the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry.
2015-04-20	Mr. Bonney was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until December, 2014, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Valuation Committee and is Chairman of the Governance and Nominating Committee of each Fund. Mr. Bonney is also a Director of Alnylam Pharmaceuticals, Inc. and is Chairman of the Board of Trustees of Bates College. He holds a BA degree from Bates College.
2016-04-18	Mr. Bonney has been a Partner at Third Rock Ventures since 2016 and was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry.
2017-04-18	Mr. Bonney was a Partner at Third Rock Ventures until 2016 and was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry.
2018-04-18	Mr. Bonney is the Chief Executive Officer and Chairman of the Board of Trustees of Kaleido Biosciences and was a Partner at Third Rock Ventures until 2016 and Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry.

abrdn Life Sciences Investors

Filing Date	Source Excerpt
2012-04-30	Mr. Bonney is the President, Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He holds an BA degree from Bates College.
2013-04-25	Mr. Bonney is the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He holds an BA degree from Bates College.
2014-04-30	Mr. Bonney is the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc., providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He holds a BA degree from Bates College.
2015-04-20	Mr. Bonney was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until December, 2014, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry. He serves on the Valuation Committee and is Chairman of the Governance and Nominating Committee of each Fund. Mr. Bonney is also a Director of Alnylam Pharmaceuticals, Inc. and is Chairman of the Board of Trustees of Bates College. He holds a BA degree from Bates College.
2016-04-18	Mr. Bonney has been a Partner at Third Rock Ventures since 2016 and was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing each Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry.
2017-04-18	Mr. Bonney was a Partner at Third Rock Ventures until 2016 and was the Chief Executive Officer and member of the Board of Directors of Cubist Pharmaceuticals, Inc. until January, 2015, providing the Fund with valuable insight into operating matters relating to biotech companies and the overall healthcare industry.
2018-04-18	Mr. Bonney is the Chief Executive Officer and Chairman of the Board of Trustees of Kaleido Biosciences and was a Partner at Third Rock Ventures until 2016.

BRISTOL MYERS SQUIBB CO

Filing Date	Source Excerpt
2020-03-25	Michael W. Bonney Director Since: 2019 Age: 61 Board Committees • Audit Committee • Science & Technology Committee ...Michael W. Bonney received $48,413 total compensation in 2019.
2021-03-25	Michael W. Bonney Director Since: 2019Age: 62 Board Committees • Audit Committee • Science & Technology Committee Other Public Boards • Kaleido Biosciences, Inc. (Chair) • Alnylam Pharmaceuticals (Chair) • Magenta Therapeutics (Chair) Former • Celgene Corporation • Global Blood Therapeutics, Inc. • Sarepta Therapeutics Inc. • Syros Pharmaceuticals Experience • Chair of the Board of Kaleido Biosciences, Inc.(2020-present); Executive Chair of the Board of Kaleido Biosciences, Inc. (2018-2020); Chief Executive Officer and Chairman (2017-2018) • Partner of Third Rock Ventures, LLC (January-July 2016) • Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. until acquired by Merck & Co., Inc. (2003-2014) • Vice President, Sales and Marketing at Biogen, Inc. (1998-2001) • Spent eleven years at Zeneca Pharmaceuticals (1984-1995) • Chair of the Board of Trustees of Bates College (2010–2019) Key Skills and Experience • Public Company CEO / CFO • Healthcare • Financial • Science / Technology / Innovation Other • Director of Gulf of Maine Research Institute • Board of Trustees of the non-profit Rare

Filing Date

Source Excerpt

2020-03-25

Michael W. Bonney Director Since: 2019 Age: 61 Board Committees • Audit Committee • Science & Technology Committee ...Michael W. Bonney received $48,413 total compensation in 2019.

2021-03-25

Michael W. Bonney Director Since: 2019Age: 62 Board Committees • Audit Committee • Science & Technology Committee Other Public Boards • Kaleido Biosciences, Inc. (Chair) • Alnylam Pharmaceuticals (Chair) • Magenta Therapeutics (Chair) Former • Celgene Corporation • Global Blood Therapeutics, Inc. • Sarepta Therapeutics Inc. • Syros Pharmaceuticals Experience • Chair of the Board of Kaleido Biosciences, Inc.(2020-present); Executive Chair of the Board of Kaleido Biosciences, Inc. (2018-2020); Chief Executive Officer and Chairman (2017-2018) • Partner of Third Rock Ventures, LLC (January-July 2016) • Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. until acquired by Merck & Co., Inc. (2003-2014) • Vice President, Sales and Marketing at Biogen, Inc. (1998-2001) • Spent eleven years at Zeneca Pharmaceuticals (1984-1995) • Chair of the Board of Trustees of Bates College (2010–2019) Key Skills and Experience • Public Company CEO / CFO • Healthcare • Financial • Science / Technology / Innovation Other • Director of Gulf of Maine Research Institute • Board of Trustees of the non-profit Rare

Sarepta Therapeutics, Inc.

Filing Date	Source Excerpt
2018-04-26	Michael W. Bonney has served as a member of our Board since December 2017. He also serves as a member of the audit committee. From June 2017, Mr. Bonney has been serving as Chief Executive Officer and Chair of Kaleido Biosciences, a biotechnology company focused on the development of novel chemistries to unlock the power of the human microbiome. From January 2016 to July 2016, Mr. Bonney was a partner at Third Rock Ventures. From January 2002 to December 2014, Mr. Bonney worked at Cubist Pharmaceuticals Inc., where he served as President and Chief Operating Officer, and then as Chief Executive Officer and a member of the Board of Directors. Mr. Bonney is Chair of the Board of Alnylam Pharmaceuticals, Inc. and a member of the Board and the Audit Committee of Magenta Therapeutics and Celgene Corporation. He also serves as a member of the Finance and the Development Committees of the Board of Whitehead Institute for Biomedical Research. Additionally, Mr. Bonney chairs the Board and serves on the Nominating and Corporate Governance and the Valuation Committees of Tekla Healthcare and Life Sciences Funds, and he chairs the Board of Trustees of Bates College. Mr. Bonney served as a member of the Compensation and the Nominating and Corporate Governance Committees of Global Blood Therapeutics from February 2016 to June 2017. He was also a director of NPS Pharmaceuticals, Inc. from 2005 until its sale to Shire plc in February 2015, where he was a member of the Audit and Compensation Committees and chaired the Nominating and Corporate Governance Committee. Mr. Bonney earned a B.A. in Economics from Bates College.
2019-04-26	Mr. Bonney has served as the Executive Chair of Kaleido’s Board since June 2017. From January 2002 to December 2014, Mr. Bonney worked at Cubist Pharmaceuticals Inc., where he served as President and Chief Operating Officer, and then as Chief Executive Officer and a member of the Board. Mr. Bonney is the Chair of the Board of Alnylam Pharmaceuticals, Inc., Chair and a member of the Board and the Audit Committee of Magenta Therapeutics, Chair and a member of the Board and the Audit Committee of Celgene Corporation and a member of the Board and the Audit Committee of Syros Pharmaceuticals, Inc.

Filing Date

Source Excerpt

2018-04-26

Michael W. Bonney has served as a member of our Board since December 2017. He also serves as a member of the audit committee. From June 2017, Mr. Bonney has been serving as Chief Executive Officer and Chair of Kaleido Biosciences, a biotechnology company focused on the development of novel chemistries to unlock the power of the human microbiome. From January 2016 to July 2016, Mr. Bonney was a partner at Third Rock Ventures. From January 2002 to December 2014, Mr. Bonney worked at Cubist Pharmaceuticals Inc., where he served as President and Chief Operating Officer, and then as Chief Executive Officer and a member of the Board of Directors. Mr. Bonney is Chair of the Board of Alnylam Pharmaceuticals, Inc. and a member of the Board and the Audit Committee of Magenta Therapeutics and Celgene Corporation. He also serves as a member of the Finance and the Development Committees of the Board of Whitehead Institute for Biomedical Research. Additionally, Mr. Bonney chairs the Board and serves on the Nominating and Corporate Governance and the Valuation Committees of Tekla Healthcare and Life Sciences Funds, and he chairs the Board of Trustees of Bates College. Mr. Bonney served as a member of the Compensation and the Nominating and Corporate Governance Committees of Global Blood Therapeutics from February 2016 to June 2017. He was also a director of NPS Pharmaceuticals, Inc. from 2005 until its sale to Shire plc in February 2015, where he was a member of the Audit and Compensation Committees and chaired the Nominating and Corporate Governance Committee. Mr. Bonney earned a B.A. in Economics from Bates College.

2019-04-26

Mr. Bonney has served as the Executive Chair of Kaleido’s Board since June 2017. From January 2002 to December 2014, Mr. Bonney worked at Cubist Pharmaceuticals Inc., where he served as President and Chief Operating Officer, and then as Chief Executive Officer and a member of the Board. Mr. Bonney is the Chair of the Board of Alnylam Pharmaceuticals, Inc., Chair and a member of the Board and the Audit Committee of Magenta Therapeutics, Chair and a member of the Board and the Audit Committee of Celgene Corporation and a member of the Board and the Audit Committee of Syros Pharmaceuticals, Inc.

Data sourced from SEC filings. Last updated: 2025-08-30